HEKMA is a patient-centric AI platform built by medical doctors, AI specialists, and enterprise solution architects β connecting underrepresented populations to clinical trials and generating new revenue streams for clinics and hospitals.
$17.7B
Global patient recruitment market
25K+
Patients matched to trials
500+
Active clinical trials
40+
Countries served
7,000+
Rare diseases addressed
300M
Rare disease patients globally
Clinical Trials & Patient Care
A Secure & Privacy-Protected Information Exchange to power next-generation clinical research β HIPAA, SOC 2 & 21 CFR Part 11 compliant.
HEKMA AI Platform β a comprehensive approach to patient recruitment combining three powerful pillars.
Trial-to-Patient Β· Patient-to-Trial
Deploy Hekma AI at hospital sites to securely scan EHR data, surface eligible patients, and connect them to registered and unregistered studies β all within a HIPAA-compliant environment.
Global PAG Connect Β· Digital Patient Community
Partner with 300+ Patient Advocacy Groups worldwide to digitally connect like patients, share resources, empower education, and enhance clinical trial awareness at scale.
Indication-Specific Β· Intelligent EHR Access
End-to-end outreach from indication targeting and IRB-approved digital campaigns through online screening, e-consent, pre-qualification, and qualified lead delivery.
The clinical trial landscape systematically underrepresents the very populations most affected by disease.
of clinical trial participants were Black β despite Black Americans being twice as likely to develop prostate cancer.
of trial participants were Asian-American, despite representing 5.9% of the US population.
of drug trials prior to 2018 didn't include any Native American or Alaska Native participants.
of clinical trial participants are Latino β while Latinos make up ~18% of the US population.
HEKMA is purpose-built to fix this β by going where patients are and connecting underrepresented communities to life-changing research.
Built by medical doctors, AI specialists, and enterprise solution experts with experience at BioMarin, Genentech, Gilead, Bristol Myers Squibb, Sangamo, and Incyte.
Mubarack Muthalif
CEO & Co-Founder
Syed Ahmed
CBO
Saba Sile
CMO
Genie Saleh
VP Sales & Partnerships
Humayun Irshad
COE β Head of AI
Team alumni from
Strategic regional collaboration partner Oltkan for the Middle East. Saudi Arabia serves as a primary site for 7 studies, with advanced healthcare infrastructure bridging regional patients to global trials.
Headquartered in the San Francisco Bay Area with an engineering center in Chennai, India. Partnering with leading research institutions across the US.
Security & Privacy
HEKMA is built on a foundation of clinical-grade security and global privacy compliance β protecting every patient, PAG, sponsor, CRO, and research site on the platform.
Explore Our Security StandardsHIPAA Compliant
Protected health information safeguards
GDPR Ready
EU data subject rights & cross-border transfers
SOC 2 Type II
Annual third-party security audit
ISO 27001
Information security management standard
UAE PDPL
UAE Personal Data Protection Law
21 CFR Part 11
FDA electronic records & audit trails
ICH GCP E6(R3)
Good Clinical Practice β current revision
Privacy by Design
Data minimisation built into architecture
Whether you're a patient looking for a trial, a sponsor accelerating drug development, or a hospital generating new revenue β HEKMA connects you.